The New Jersey Department of Health currently lists SSUS Federal CDC Supplemental 2027 under the Division of Syndemic and Substance Use Services for the FY 2026-2027 grant cycle. The current NJDOH directory shows an application deadline of September 18, 2026. The public materials available to Atlas do not state an exact submission time or timezone.
The verified NJDOH notice identifies an estimated $1,100,000 program total for the October 1, 2026 through May 31, 2027 award period. The program supports innovative HIV prevention and diagnosis approaches with linkage to care, including whole-person status-neutral services, HIV testing, linkage to care, PrEP initiation, and other scientifically supported interventions.
Eligible applicant categories identified in the verified notice include municipal government, county government, institutions of higher education, hospitals, and 501(c)(3) nonprofit organizations. Applicants must currently provide, or demonstrate capacity to provide, the services for which funding is sought and must comply with applicable NJDOH HIV/AIDS reporting and SAGE grant requirements.
The controlling RFA remains necessary before applicant pursuit to verify any applicant-specific award ceiling, match or cost-share terms, detailed allowable and ineligible costs, vendor and procurement rules, required attachments and forms, and the final submission mechanics. Atlas will not infer those items.
Atlas assessment: Atlas Opportunity Score 84/100. N9+ Fit Score 58/100, conditional. The Nonagon N9+ device and platform may have a supporting role in low-barrier clinical assessment or connected care workflows where an eligible applicant’s approved HIV prevention and linkage model requires those capabilities, but no N9+ cost or vendor role is represented as grant-allowable until the controlling RFA and applicant procurement rules confirm it. Dr. Miltie/QC Healthcare is not being advanced as a direct applicant.